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The development of the CRISPR-Cas system is
revolutionizing genome editing in a variety of organisms.
The system has now been used to manipulate the
genome of Plasmodium falciparum, the most lethal
malaria-causing species. The ability to generate gene
deletions or nucleotide substitutions rapidly and
economically promises to accelerate the analysis of novel
drug targets and to help elucidate the function of
specific genes or gene families, while complementing
genome-wide association studies.Gene disruption in P. falciparum traditionally requiresGenetic manipulation of the malaria parasite
The global malaria burden exceeds 200 million infections
per year, resulting in over 600,000 deaths annually. Most
fatalities are attributable to blood-stage infections by the
apicomplexan parasite Plasmodium falciparum. The current
frontline treatments are artemisinin-based combination
therapies, whose clinical use is at the scale of hundreds of
millions of doses per year. The recent emergence of resist-
ance to artemisinin in South East Asia is of global con-
cern, given the devastating loss of the former frontline
therapies chloroquine and pyrimethamine-sulfadoxine to
drug-resistant strains of P. falciparum [1].
Genetic crosses and genome-wide association studies
(GWAS) have been instrumental in uncovering candidate
genes that are involved in resistance phenotypes. Neverthe-
less, confirmation of their actual contribution to resistance
requires efficient tools to genetically modify P. falciparum
parasites cultured in vitro. These transgenic lines could
also be used to generate insights into the underlying mech-
anisms of drug action and parasite resistance. Genetic
methodologies are also increasingly used to dissect molecu-
lar components of P. falciparum pathogenesis, including* Correspondence: df2260@columbia.edu
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Steady progress has been made in transforming P. fal-
ciparum into a genetically tractable laboratory organism.
Important milestones include the establishment of in vitro
culture systems in 1979, transfection techniques in 1995,
and the sequencing of the genome in 2002 [1]. Neverthe-
less, methods to engineer the P. falciparum genome have
been hampered by limited tools and inefficiencies in trans-
fection and integration. Furthermore, RNA interference
(RNAi) is not effective in P. falciparum, unlike mamma-
lian systems.
one to three months of continuous culture before one can
observe a stochastic homologous recombination event
that leads to the integration of an episomally maintained
plasmid by either a single- or a double-crossover (Figure 1A).
Similar recombination-dependent approaches are used for
allelic exchange, for example, to validate potential drug-
resistance mutations [1]. The inherent inefficiency of this
process has precluded any large-scale gene deletion cam-
paigns, with few exceptions such as the heroic effort that
was successful in disrupting 53 out of 83 targeted genes
that had potential roles in protein export into the host
red blood cells (RBCs) [2]. As described below, genome
editing techniques based on the RNA-guided CRISPR
(clustered regularly interspaced short palindromic repeats)-
Cas (CRISPR-associated proteins) system have now been
reported for P. falciparum [3], providing a powerful new
approach that can be used to interrogate the malarial
parasite genome.Harnessing the power of the double-strand break:
genome editing using site-specific nucleases
A double-strand break (DSB) in the chromosome of a cell
is a potentially catastrophic event, and as a consequence,
organisms have developed mechanisms to deal with this
contingency. One emergency measure is non-homologous
end joining (NHEJ), which simply stitches together the
broken DNA ends in a process that can introduce smallral Ltd. The licensee has exclusive rights to distribute this article, in any medium, for 12
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Figure 1 Genome modification strategies for P. falciparum. (A) Conventional allelic exchange or knockout strategies rely on a rare homology-driven
integration event, probably resulting from a stochastic double-strand break (DSB) near the target site (asterisk). This approach requires several weeks to
months of continuous culture, and yields a complex genomic locus after crossover-mediated recombination that includes a selectable marker and
duplicated gene fragments. By contrast, genome-editing approaches are driven by a directed DSB event, mediated by site-specific nucleases expressed
from transfected plasmids, triggering homology-directed repair from a donor template to yield gene disruptions or nucleotide substitutions (asterisk).
(B) In ZFN-based editing, heterodimerization of an engineered pair of ZFNs (ZFN-L and ZFN-R) each fused to a split FokI domain (red) yields a functional
nuclease that recognizes the specified target site. (C) The two-component CRISPR-Cas system consists of a constant nuclease, Cas9, which is directed to
the desired location by RNA-DNA base pairing dictated by an expressed gRNA.
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more precise method of homology-directed repair, using
a homologous template to guide the repair [4]. Genome
editing harnesses these processes experimentally to dis-
rupt or modify genomic loci in defined ways. The com-
mon theme with all genome editing approaches is the use
of a site-specific nuclease that cleaves the genome at a de-
fined site, thus triggering a repair event that can be guided
to yield outcomes ranging from complete gene deletion to
more subtle sequence alterations [5].
Customized zinc-finger nucleases (ZFNs), in which the
catalytic domain of the Fok1 nuclease is combined with
multiple zinc-finger proteins that specify the DNA-binding
site, were the first nucleases to be used widely for genome
editing in a variety of organisms, including P. falciparum.
These nucleases allowed parasites with targeted deletions
or allelic replacements to be generated considerably faster
than had been possible using conventional methods
because ZFN-generated DSB events occur shortly after
transfection, rather than weeks to months later [6]. More
significantly, perhaps, template-guided repair of the DSB
allows for the delivery of as little as a single-base change,
an application ideally suited for testing the impact of puta-
tive drug resistance mutations (Figure 1B). The recombin-
ant locus that results from ZFN editing contrasts with the
complex locus formed by conventional allelic exchange,which often includes the selectable marker, thus preclud-
ing its use in downstream applications and a partial dupli-
cation of the targeted gene (resulting from crossover-
mediated plasmid integration; Figure 1A). ZFN editing is a
powerful approach, but the cost and non-trivial nature of
designing zinc-finger proteins that bind specific sequences
necessitates specialized knowledge and limits the scale at
which they can be deployed.
A new platform for gene editing: CRISPR-Cas
An alternative system for genome editing avoids the
ZFN design problem by using RNA-DNA base pairing
to guide DNA cleavage. CRISPR-Cas systems function in
bacterial adaptive immunity as a defense against viruses
or other invasive DNA. The CRISPR sequences, acquired
initially from foreign DNA, are arrayed in the host
bacterial genome and are transcribed and processed to
generate short guide RNAs (gRNAs) that direct the Cas
endonuclease to complementary target sites. The ease
with which the Cas nuclease can be reprogrammed by
supplying alternative gRNAs has led to its exceptionally
rapid adoption as a genetic tool in a wide variety of or-
ganisms [7].
The first 20 nucleotides at the 5′ end of the gRNA de-
termine specificity by homology to the target site, with
an additional sequence requirement in the genome of an
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downstream of the target site. To date, the most com-
mon use in mammalian systems has been to generate
loss-of-function alleles by directed cleavage followed by
error-prone NHEJ. This approach has permitted not
only the targeting of individual genes but also large-scale
genetic screens that employ libraries of over 87,000 dis-
tinct gRNAs [8].
CRISPR-Cas gene editing in Plasmodium parasites
A new study by Ghorbal et al. [3] published in Nature
Biotechnology has brought the power of the CRISPR-Cas
system to P. falciparum. Two distinct applications, gene
disruption and single-nucleotide gene editing, were dem-
onstrated, highlighting the versatility of this approach.
Parasites with disruptions at two non-essential loci, an
integrated green fluorescent protein (GFP) reporter gene
and the kahrp gene, which encodes a protein exported
into the host RBC, were efficiently obtained by insertion
of a selectable marker within their coding sequences.
Similarly effective were more subtle experiments that
modified the sequences of two genes, orc1 and kelch13,
which have putative roles in gene silencing and emerging
resistance to artemisinin, respectively. Parasites that
were altered at the appropriate sites were recovered with
very high efficiency, despite there being no direct selec-
tion for the modification but only for the transfected
plasmids, suggesting that neutral or even deleterious mu-
tations can be generated using this system. As with earlier
ZFN-editing experiments [6], the desired alterations were
probably enriched within the bulk parasite population by
the inclusion of silent mutations in the donor sequence
that protected both the donor plasmid and edited gen-
omic locus from cleavage. Furthermore, for reasons ex-
plained below, the ability to place the DSB site in very
close proximity to the desired modification is another
driver of efficient editing.
A two-plasmid approach was used by Ghorbal et al.
[3] to express both the Cas9 nuclease and the gRNA
(Figure 1C). Because of the requirement for a precise
transcriptional start site for the gRNA, expression in
mammalian cells has typically utilized the promoter of
the U6 small nuclear RNA (snRNA) component of the
spliceosome. U6 snRNA transcription is dependent on
RNA polymerase III, which precisely transcribes a variety
of non-protein-coding RNAs. Transcription of the U6
product initiates with a guanosine nucleotide, placing
some constraint on the selection of target sequences in the
genome, which optimally consist of the motif G-N19-NGG,
with the final three nucleotides (the PAM sequence) critical
for cleavage. One notable finding of the Ghorbal et al. study
[3] is that the use of the P. falciparum U6 snRNA upstream
regulatory region was able to drive expression of gRNAs
in the parasite, but apparently without the functionalrequirement for the initial guanosine nucleotide. This is
significant because it greatly expands the potential tar-
get sites within the parasite genome to any sequence
with the -NGG PAM motif, a particularly liberating fea-
ture for an organism that has an average GC content of
only 19.4%.
One quirk of Plasmodium biology is that these parasites
appear to lack the machinery for NHEJ [6]. Thus, the most
basic and scaleable application of the CRISPR-Cas system,
cleavage followed by error-prone repair to generate frame-
shift mutations, is not available to malaria researchers.
Nevertheless, an enticing array of other possibilities awaits
the field. The ability to express two or more gRNAs within
the same cell may permit multiplex cleavage events that
can generate large deletions, which could be used to inves-
tigate genome duplications that are often associated with
drug resistance. In mammalian systems, a nuclease-dead
version of Cas9, guided to a target gene, has been shown
to act as a roadblock to transcription. Conversely, fusion
of this inactive Cas9 to a transcriptional activation domain
can increase gene expression [9]. Development of these
gene regulatory approaches for Plasmodium would more
than fill the gap left by the absence of RNAi tools for the
parasite.
Robust, inexpensive methods to manipulate the parasite
genome efficiently should now accelerate the discovery of
new drug targets, the validation of GWAS data from field
and clinical samples, and the identification of genes that
are important for the critical parasite transitions between
the human and mosquito hosts. The best new technolo-
gies offer not just improvements to existing methods but
transform the very nature of the questions we can ask.
The malaria parasite has joined the CRISPR-Cas revolu-
tion, and as these tools are brought to bear on a pathogen
that is both deadly and biologically fascinating, we eagerly
await the insights that are sure to follow.
Note added in proof
A recent report by Zhang et al. [10] describes the use of
CRISPR/Cas systems to modify the genome of the rodent
malaria parasite, Plasmodium yoelii.
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